Drug therapy advances have slashed the rate of hypos: study
Danish data highlight the relatively greater risk with use of human insulins and sulfonylureas, researchers say
Development of insulin analogues and newer drug classes for diabetes likely lie behind a fall of more than 60% in hospital admissions for hypoglycaemia, Danish researchers say.
Among patients with type 2 diabetes, the move away from sulfonylureas to metformin, DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors has increased patient safety, their study suggests.
Using data from the Danish National Patient Registry and the Danish Medicines Agency, the team tracked first hospitalisations for hypoglycaemia for people diagnosed with diabetes between 1998 and 2018.
They also recorded medications the patients were on, and other variables, such as age and diabetes duration, in a bid to explain the trends.
